SCHEMBL3087579

SCHEMBL3087579

CC(C)(C)NS(=O)(=O)c1ccc(N)c(Br)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.58
CA2 P00918 2/20 0.58
CA9 Q16790 2/20 0.58
CA12 O43570 1/20 0.58
CA4 P22748 1/20 0.58
CA6 P23280 1/20 0.58
CA5A P35218 1/20 0.58
CA7 P43166 1/20 0.58
CA14 Q9ULX7 1/20 0.58
CA5B Q9Y2D0 1/20 0.58
MAPT P10636 3/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
KDM4E B2RXH2 2/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
NPC1 O15118 1/20 0.51
LMNA P02545 1/20 0.51
HPGD P15428 1/20 0.51
RAB9A P51151 1/20 0.51
PARG Q86W56 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1369496 0.81 LMNA (0.53) MAPTSMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL20767241 0.81 CA1 (0.63) CA1CA2CA9CA12CA4
SCHEMBL29909892 0.81 CA1 (0.63) CA1CA2CA9CA12CA4
SCHEMBL29715377 0.80 CA1 (0.56) CA1CA2CA9CA12CA4
SCHEMBL21190881 0.80 KMT2A (0.51) MAPTSMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL23092401 0.80 CA1 (0.56) CA1CA2CA9CA12CA4
SCHEMBL957480 0.78 MEN1 (0.53) MAPTSMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL1303842 0.78 PKM (0.60) MAPTSMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL29498627 0.77 KMT2A (0.51) MAPTSMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL19994876 0.77 KMT2A (0.51) MAPTSMN1; SMN2KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 US disclosed
CN-101466686-A C-FMS kinase inhibitor JANSSEN PHARMACEUTICA NV (BE) 2009-06-24 CN disclosed
EP-2016057-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-01-21 EP disclosed
WO-2007123516-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-11-01 WO disclosed
US-20060258666-A1 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2006-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258666-A1 c-fms kinase inhibitors FLT3, FES, FER CA1 3066/4885CA2 710/4885CA9 2019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.